Sinovac Biotech


Sinovac Biotech Ltd. is a biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. The company is based in Beijing, China.
Sinovac's commercialized vaccines include Healive, Bilive, Anflu, Panflu and PANFLU.1. Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine.
Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.
In mid-April 2020, China approved a clinical trial for a candidate COVID-19 vaccine developed by Sinovac. The vaccine, called CoronaVac, is a chemically-inactivated whole virus vaccine for COVID-19.